Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models.

Reinert J, Martens H, Huettenrauch M, Kolbow T, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Bayer TA, Wirths O.

J Alzheimers Dis. 2014;39(4):871-81. doi: 10.3233/JAD-131373.

PMID:
24305500
2.

APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38.

Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, Saccucci S, Di Fede G, Catania M, Walsh DM, Demarchi A, Rozemuller A, Bogdanovic N, Bugiani O, Ghetti B, Tagliavini F.

Acta Neuropathol. 2012 Dec;124(6):809-21. doi: 10.1007/s00401-012-1061-x. Epub 2012 Nov 13. Erratum in: Acta Neuropathol. 2013 Mar;125(3):467.

PMID:
23143229
3.

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.

Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, Wiltfang J, Kovacs GG, Ingelsson M, Lannfelt L, Paetau A, Bergquist J, Wirths O.

Acta Neuropathol Commun. 2016 Mar 8;4:24. doi: 10.1186/s40478-016-0294-7.

4.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2010 Jan;117(1):85-96. doi: 10.1007/s00702-009-0314-x. Epub 2009 Oct 13.

5.

Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Guzmán EA, Bouter Y, Richard BC, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Wirths O, Bayer TA.

Mol Neurodegener. 2014 Apr 2;9:13. doi: 10.1186/1750-1326-9-13.

6.

Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.

Hunter JM, Bowers WJ, Maarouf CL, Mastrangelo MA, Daugs ID, Kokjohn TA, Kalback WM, Luehrs DC, Valla J, Beach TG, Roher AE.

J Alzheimers Dis. 2011;27(2):361-76. doi: 10.3233/JAD-2011-110608.

7.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Güntert A, Döbeli H, Bohrmann B.

Neuroscience. 2006 Dec 1;143(2):461-75. Epub 2006 Sep 27.

PMID:
17008022
8.

N-truncated Aβ2-X starting with position two in sporadic Alzheimer's disease cases and two Alzheimer mouse models.

Savastano A, Klafki H, Haußmann U, Oberstein TJ, Muller P, Wirths O, Wiltfang J, Bayer TA.

J Alzheimers Dis. 2016;49(1):101-10. doi: 10.3233/JAD-150394.

PMID:
26529393
9.

Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits.

Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Duff K, Tsuji S, Hashimoto T, Iwatsubo T.

Am J Pathol. 2004 Jul;165(1):273-81.

10.

Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models.

Kumar-Singh S.

Int J Mol Sci. 2009 Apr 23;10(4):1872-95. doi: 10.3390/ijms10041872. Review.

11.

Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.

Wang T, Wang CY, Shan ZY, Teng WP, Wang ZY.

J Alzheimers Dis. 2012;29(3):549-59. doi: 10.3233/JAD-2011-111874.

PMID:
22269164
12.

Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.

Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira J, Tabira T.

FASEB J. 2005 Feb;19(2):255-7. Epub 2004 Nov 17.

PMID:
15548589
13.

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L.

Am J Pathol. 2004 Oct;165(4):1289-300.

14.

Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.

O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X.

Brain Pathol. 2008 Oct;18(4):548-61. doi: 10.1111/j.1750-3639.2008.00152.x. Epub 2008 Apr 11.

15.

AMY plaques in familial AD: comparison with sporadic Alzheimer's disease.

Lippa CF, Schmidt ML, Nee LE, Bird T, Nochlin D, Hulette C, Mori H, Lee VM, Trojanowski JQ.

Neurology. 2000 Jan 11;54(1):100-4.

PMID:
10636133
16.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
17.

Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.

Xia W, Zhang J, Ostaszewski BL, Kimberly WT, Seubert P, Koo EH, Shen J, Selkoe DJ.

Biochemistry. 1998 Nov 24;37(47):16465-71.

PMID:
9843412
18.

The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, Wirths O, Bayer TA, Nilsson LN, Basun H, Lannfelt L, Ingelsson M.

Acta Neuropathol Commun. 2013 Sep 10;1:60. doi: 10.1186/2051-5960-1-60.

19.
20.

Peripheral amyloid levels present gender differences associated with aging in AβPP/PS1 mice.

Ordóñez-Gutiérrez L, Antón M, Wandosell F.

J Alzheimers Dis. 2015;44(4):1063-8. doi: 10.3233/JAD-141158.

PMID:
25408213

Supplemental Content

Support Center